Heart Failure Drug
-
{
- All
- News
-
Heart Drug Launch Could be 'Most Exciting Ever', Says Novartis
The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.
-
5 Early Warning Signs Of Heart Failure
Hence, it is important to understand the early symptoms of heart failure to prevent the condition from exacerbating.
-
Lower Doses of Heart Medicines Save Lives: Study
People who suffered a heart attack lived longer when their dose of a medication known as a beta-blocker was a quarter of the amount commonly prescribed, researchers said Monday.
-
Lower Doses of Heart Medicines Save Lives: Study
People who suffered a heart attack lived longer when their dose of a medication known as a beta-blocker was a quarter of the amount commonly prescribed, researchers said Monday.
-
Heart Drug Launch Could be 'Most Exciting Ever', Says Novartis
The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.
-
Heart Drug Launch Could be 'Most Exciting Ever', Says Novartis
The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.
-
5 Early Warning Signs Of Heart Failure
Hence, it is important to understand the early symptoms of heart failure to prevent the condition from exacerbating.
-
Lower Doses of Heart Medicines Save Lives: Study
People who suffered a heart attack lived longer when their dose of a medication known as a beta-blocker was a quarter of the amount commonly prescribed, researchers said Monday.
-
Lower Doses of Heart Medicines Save Lives: Study
People who suffered a heart attack lived longer when their dose of a medication known as a beta-blocker was a quarter of the amount commonly prescribed, researchers said Monday.
-
Heart Drug Launch Could be 'Most Exciting Ever', Says Novartis
The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.
